AXIS Medical Education

Welcome to
AXIS Medical Education

Where Education and Clinical Practice Intersect^®

Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
CME/CE
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
0.25 credits
- Sara M. Tolaney, MD, MPH
0.25 credits
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
CME/CE
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
0.50 credits
- Adam Brufsky, MD, PhD
0.50 credits
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
CME/CE
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
0.50 credits
- Helena Yu, MD
0.50 credits
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
CME/CE
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
0.25 credits
- Sara M. Tolaney, MD, MPH
0.25 credits
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: Cytogenetic Testing and PARP Inhibition for Maintenance Treatment
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: Cytogenetic Testing and PARP Inhibition for Maintenance Treatment
CME/CE
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: Cytogenetic Testing and PARP Inhibition for Maintenance Treatment
1.00 credit
- Kathleen Moore, MD, MS, FASCO
1.00 credit
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: PARP Inhibitor-Related Adverse Events and Team-Based Care
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: PARP Inhibitor-Related Adverse Events and Team-Based Care
CME/CE
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: PARP Inhibitor-Related Adverse Events and Team-Based Care
1.00 credit
- Kathleen Moore, MD, MS, FASCO
1.00 credit
Expert Answers to Common Questions for Tailoring ADC Therapies Across the HER2 Spectrum in Metastatic Breast Cancer
Expert Answers to Common Questions for Tailoring ADC Therapies Across the HER2 Spectrum in Metastatic Breast Cancer
CME/CE
Expert Answers to Common Questions for Tailoring ADC Therapies Across the HER2 Spectrum in Metastatic Breast Cancer
0.25 credits
- Sara M. Tolaney, MD, MPH
0.25 credits
Expert Answers to Common Questions for Improving the Road to Remission with CAR T-Cell Therapies in Large B-Cell Lymphoma: Considerations for Community Practice
Expert Answers to Common Questions for Improving the Road to Remission with CAR T-Cell Therapies in Large B-Cell Lymphoma: Considerations for Community Practice
CME/CE
Expert Answers to Common Questions for Improving the Road to Remission with CAR T-Cell Therapies in Large B-Cell Lymphoma: Considerations for Community Practice
0.25 credits
- Caron A. Jacobson, MD
0.25 credits

CME

Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
CME/CE
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
0.50 credits
- Sagar Lonial, MD, FACP
- Meghan Berkenstock, MD
- Saad Z. Usmani, MD, MBA, FACP
0.50 credits
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
CME/CE
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
0.50 credits
- Matthew S. Davids, MD, MMSc
0.50 credits
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
CME/CE
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
0.50 credits
- Joshua E. Reuss, MD
0.50 credits
Practical Applications for Quality Improvement in Myelofibrosis Management: A Video Brief on Lessons Learned
Practical Applications for Quality Improvement in Myelofibrosis Management: A Video Brief on Lessons Learned
Oncology and Hematology
Practical Applications for Quality Improvement in Myelofibrosis Management: A Video Brief on Lessons Learned
- Joseph Kim, MD, MPH
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
CME/CE
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
0.50 credits
- Matthew Lunning, DO, FACP
0.50 credits